Restoring 24-hour Substrate Rhythmicity to Improve Glycemic Control by Timing of Lifestyle Factors

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age45-75
SponsorUniversité de Sherbrooke

About this trial

Exercise is well-known to improve skeletal muscle energy metabolism and is an established intervention to improve muscle insulin sensitivity and to counter the development of type 2 diabetes (T2D). However, given the 24h rhythmicity in substrate metabolism previously observed in healthy, lean men and the lack of such rhythmicity in men with insulin-resistance, the investigator hypothesize that appropriate timing of exercise training can maximize the metabolic health effects of exercise. Indeed, a preliminary study in humans revealed that afternoon high-intensity interval training (HIIT) exercise was more effective than morning exercise in improving 24h blood glucose levels in men with T2D. Another recent study in mice showed that the time of day is a critical factor in augmenting the beneficial effects of exercise on the skeletal muscle metabolome as well as on whole-body energy homeostasis. However, human studies that specifically target the impact of timing of exercise training on glucose homeostasis and metabolic health are scarce and the potential underlying mechanisms largely unknown.

The overarching goals of this project is to improve 24-hour rhythmicity of metabolism in men and women with prediabtes by appropriate timing of exercise and to assess its effect on metabolic health and immune response. Acute and prolonged exercise interventions timed in the morning vs late afternoon will be carried out in individuals with prediabetes to determine whether acute exercise in the afternoon and prolonged exercise training in the afternoon can improve peripheral insulin sensitivity, compared to exercise in the morning, and positively affect adipose tissue dietary fatty acid storage and partitioning of dietary fatty acids in skeletal muscles.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Fasting plasma glucose: 6.1 to 6.9 mmol/L or

2-hour plasma glucose post 75g OGTT: 7.8 to 11.0 mmol/L and

HbA1c: 6.0 to 6.4%

or Insulin resistant: glucose clearance rate ≤ 360 ml/kg/min as determined using the Oral Glucose Insulin Sensitivity Index at Time 120 min.

Disqualifiers

overt cardiovascular disease as assessed by medical history, physical exam, and abnormal ECG

Treatment with any drug known to affect lipid or carbohydrate metabolism, except statins (to be stopped 3 weeks prior to study A), metformin or anti-hypertensive drugs (to be stopped 7 days prior to the studies);

presence of liver or renal disease other than uncomplicated NASH or mild isolated proteinuria; uncontrolled thyroid disorder;

Uncontrolled severe hypertension, systolic pressure ≥ 180 mm Hg or diastolic pressure ≥ 110 mm Hg;

Trial design

Design model

Parallel

Treatments tested in this trial

  • High-intensity interval training

    Behavioral

    3 times per week high-intensity interval training (HIIT) on a cycle ergometer for 12 weeks.

Treatment groups

48 Participants
are divided into 2 treatment groups
Group A: Morning exerciseActive comparator 1 intervention
Group B: Afternoon exerciseExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change in Adipose tissue dietary fatty acid (DFA) partitioning

Determined using oral administration of \[18F\]-Fluoro-6-Thia-Heptadecanoic Acid (FTHA) during whole-body acquisition

Time frame
Measured 180 minutes, 240 minutes, 300 minutes and 360 minutes after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
2

Change in lean organ (heart, liver, skeletal muscle) DFA partitioning

Determined using oral administration of \[18F\]-Fluoro-6-Thia-Heptadecanoic Acid (FTHA) during whole-body acquisition

Time frame
Measured 180 minutes, 240 minutes, 300 minutes and 360 minutes after liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
3

Change in skeletal muscle ATP fluxes in vivo

Determined using phosphorus-31 magnetic resonance spectroscopy.

Time frame
Measured 170 minutes before and 30 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
4

Change in glucose control.

Determined using continuous glucose monitoring and repeated blood samples obtained during metabolic visit.

Time frame
Measured continuously 2-3 days before and 2-3 days after first and final exercise session, after 12-week exercise intervention.

Secondary outcomes

1

Change in adipose tissue nonesterified fatty acid (NEFA) metabolism.

Determined using \[11C\]-palmitate with dynamic PET acquisition

Time frame
Measured 150 minutes before and 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
2

Change in lean organ (heart, liver, skeletal muscle) NEFA metabolism.

Determined using \[11C\]-palmitate with dynamic PET acquisition

Time frame
Measured 150 minutes before and 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
3

Change in insulin sensitivity

Determined by measuring circulating glucose, NEFA, insulin and C-peptide following the liquid meal.

Time frame
Measured every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).
4

Change in dietary fatty acid oxidation

Determined by measuring breath \[13C\]-carbon dioxide enrichment.

Time frame
Measured every 60 minutes following liquid meal at baseline visit, 18-24hours after acute exercise bout and >48hours after final exercise bout (after 12 week intervention).

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Université de Sherbrooke

Lead sponsor

University of Calgary

Collaborator

University of Waterloo

Collaborator

Laval University

Collaborator

Wageningen University

Collaborator

Maastricht University Medical Center

Collaborator

Leiden University Medical Center

Collaborator

McMaster University

Collaborator

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborator